Dextrorazoxane review

Dextrorazoxane is a cardioprotective agent used to prevent cardiovascular conditions during chemotherapy. A substance derived from EDTA, Dextrorazoxane is considerd to interfere with substances inside cells, which may cause heart disease after using anthracyclines such as doxorubicin. How Dextrorazoxane works in protecting the heart is not fully understood. This medicament is uncommitted as Zinecard in the United States and Canada, and Cardiozane in the EU and comes in 250 mg and 500 mg vials for injection.

Dextrorazoxane is used to prevent and reduce the severity of heart conditions, which may occur during chemotherapy using anthracyclines, such as those used in the treatment of women suffering from metastatic breast cancer.

Dextrorazoxane marketed under brand name Totect or Savene has been approved for use as a treatment of extravasation caused by anthracycline chemotherapy. Extravasation occurs when anthracycline leaks out of the blood vessels and seeps into the skin.

The dosage of Dextrorazoxane depends on the trunk surface area of the affected role and the doxorubicin dosage being taken. It is usually measured in a 10:1 ratio with respect to the doxorubicin dosage. Once the proper dosage has been determined, the medicament can be administered directly into the vein via an IV push or through a quick infusion from an IV infusion bag. 30 minutes after taking Dextrorazoxane, the IV injection of doxorubicin can be given.

Dextrorazoxane is stable for about 6 hours after reconstitution when placed in an empty infusion bag at controlled room temperature ranging from 15 to 30C (59 to 86F), or placed in refrigeration at 2 to 8C (36 to 46F). It may be diluted using a 0.9% sodium chloride injection, USP or using a 5.0% dextrose injection, USP. Dilute the medicament to a concentration between 1.3 to 5.0 mg/mL and store in empty IV infusion bags. Do not use leftover solutions.

One of the side effects experienced by those undergoing Dextrorazoxane treatment is pain or swelling at the injection site. Blood counts can also be lower when taking Dextrorazoxane with chemotherapy compared to undergoing chemotherapy alone. Recovery periods for the blood counts remain similar for both cases.

Other common side effects include diarrhea, general discomfort, pyrexia, loss of appetite and nausea. More serious side effects involve hair loss, vomiting, swelling of the throat and tongue, and severe allergic reactions that require immediate medical attention.

Dextrorazoxane should only be used with anthracycline chemotherapy such as doxorubicin.

Chemotherapy may cause sterility in men and women so consult your doctor if you plan on having children. It has not yet been shown that Dextrorazoxane itself can cause sterility. If you consider you might be pregnant, inform your doctor about your condition before being given Dextrorazoxane.

You may experience greater susceptibility to infection during treatment so consult with your doctor before getting live virus vaccines to avoid complications.

Dextrorazoxane has the following structural formula:

Chemical structure of Dextrorazoxane

• Molecular formula of Dextrorazoxane is C11H16N4O4
• Chemical IUPAC Name is 4-[1-(3,5-dioxopiperazin-1-yl)propan-2-yl]piperazine-2,6-dione
• Molecular weight is 268.269 g/mol
Dextrorazoxane available : 250mg injection and 500mg injection

Generic name: Dexrazoxane

Brand name(s): Cardioxane, Desrazoxane, Dexrazoxano, Dexrazoxanum, Dyzoxane, Eucardion, Razoxana, Razoxane, Razoxanum, Razoxin, Tepirone, Troxozone, Zinecard

  Your Dextrorazoxane review